Autonomix Medical (AMIX) Investor presentation summary

Technology overview

• Proprietary transvascular technology enables real-time, high-resolution neural signal detection and targeted nerve ablation for neurological diseases.

• Microchip-based system senses, treats, and verifies nerve activity with high sensitivity (<5 μV), allowing precision-guided interventions.

• Platform supports multi-channel, 360-degree mapping for directional neuronal targeting and immediate intra-procedure feedback.

• Over 120 patents issued or pending, supporting a robust intellectual property portfolio.

Clinical results and studies

• First-in-human PoC 1 trial in pancreatic cancer pain showed statistically significant, durable pain reduction (mean 66% at 3 months) and elimination of opioid use in responders.

• Rapid onset of pain relief observed within 24 hours, with sustained benefit at 4-6 weeks and 3 months post-procedure.

• No device- or procedure-related serious adverse events reported in PoC 1; safety and efficacy endpoints met.

• PoC 2 study expands to additional visceral cancers and earlier-stage pancreatic cancer, refining procedural protocols.

Market opportunity and business strategy

• Targeting a combined $100 billion market across pain management, cardiovascular, and pulmonary indications.

• Initial focus on pancreatic cancer pain as proof of concept, with future expansion into chronic pain, cardiovascular, and pulmonary diseases.

• Revenue model includes capital equipment, disposable catheters, and annual software licenses.

• Path to FDA De Novo approval targeted for 2028, with U.S. IDE clinical trials planned.